Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.

Yamamura, Takashi; Ashtamker, Natalia; Ladkani, David; Fukazawa, Toshiyuki; Houzen, Hideki; Tanaka, Masami; Miura, Toshiro; Knappertz, Volker

Yamamura, Takashi; Ashtamker, Natalia; Ladkani, David; Fukazawa, Toshiyuki; Houzen, Hideki; Tanaka, Masami; Miura, Toshiro; Knappertz, Volker.

Afiliación

Yamamura T; Department of Immunology National Center of Neurology and Psychiatry National Institute of Neuroscience, and Multiple Sclerosis Center Tokyo Japan.
Ashtamker N; Research and Development Teva Pharmaceutical Industries Netanya Israel.
Ladkani D; Research and Development Teva Pharmaceutical Industries Netanya Israel.
Fukazawa T; Sapporo Neurology Hospital Sapporo Japan.
Houzen H; Department of Neurology Obihiro Kosei General Hospital Hokkaido Japan.
Tanaka M; Multiple Sclerosis Center Kyoto Min-iren Chuo Hospital Kyoto Japan.
Miura T; Department of Neurology Kaikoukai Josai Hospital Nagoya Japan.
Knappertz V; Department of Neurology School of Medicine Fujita Health University Aichi Japan.

Clin Exp Neuroimmunol ; 8(2): 129-137, 2017 05.

Article en En | MEDLINE | ID: mdl-28706565

Palabras clave

Japanese; T2 lesions; gadoliniumenhancing lesions; glatiramer acetate; relapsingremitting multiple sclerosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Risk_factors_studies Idioma: En Revista: Clin Exp Neuroimmunol Año: 2017 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google